Aura Biosciences, Inc. (NASDAQ:AURA) SVP Sells $10,881.00 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi sold 1,404 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total transaction of $10,881.00. Following the transaction, the senior vice president now owns 82,278 shares in the company, valued at $637,654.50. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Amy Elazzouzi also recently made the following trade(s):

• On Tuesday, January 21st, Amy Elazzouzi sold 1,001 shares of Aura Biosciences stock. The stock was sold at an average price of $7.67, for a total value of $7,677.67.

Aura Biosciences Price Performance

Aura Biosciences stock traded down $0.30 during mid-day trading on Tuesday, hitting $7.65. 213,354 shares of the company were exchanged, compared to its average volume of 139,966. Aura Biosciences, Inc. has a 12-month low of $6.63 and a 12-month high of $12.38. The business’s 50 day simple moving average is $8.07 and its two-hundred day simple moving average is $8.76. The company has a market capitalization of $382.12 million, a P/E ratio of -4.42 and a beta of 0.29.

Analysts Set New Price Targets

Several equities analysts recently issued reports on AURA shares. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $23.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Long Focus Capital Management LLC raised its position in shares of Aura Biosciences by 123.9% in the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock valued at $20,861,000 after buying an additional 1,404,228 shares during the last quarter. Levin Capital Strategies L.P. grew its stake in Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock worth $10,255,000 after acquiring an additional 783,984 shares during the period. B Group Inc. acquired a new position in Aura Biosciences in the 4th quarter valued at $3,885,000. Franklin Resources Inc. lifted its stake in shares of Aura Biosciences by 14.8% during the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock worth $15,571,000 after purchasing an additional 215,597 shares during the period. Finally, Ensign Peak Advisors Inc boosted its holdings in shares of Aura Biosciences by 43.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock worth $3,212,000 after purchasing an additional 118,000 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.